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Craniopharyngiomas (CP) are epithelial neoplasms generally found in the area of the pitu-
itary and hypothalamus. Despite benign histology, these tumors and/or their treatment
often result in signiﬁcant, debilitating disorders of endocrine, neurological, behavioral, and
metabolic systems. Severe obesity is observed in a high percentage of patients with
CP resulting in signiﬁcant comorbidities and negatively impacting quality of life. Obesity
occurs as a result of hypothalamic damage and disruption of normal homeostatic mech-
anisms regulating energy balance. Such pathological weight gain, termed hypothalamic
obesity (HyOb), is often severe and refractory to therapy. Unfortunately, neither lifestyle
intervention nor pharmacotherapy has proven effective in the treatment of HyOb. Given
the limited choices and poor results of these treatments, several groups have examined
bariatric surgery as a treatment alternative for patientswith CP–HyOb.While a large body of
evidence exists supporting the use of bariatric surgery in the treatment of exogenous obe-
sity and its comorbidities, its role in the treatment of HyOb has yet to be deﬁned. To date,
the existing literature on bariatric surgery in CP–HyOb is largely limited to case reports and
series with short term follow-up. Here we review the current reports on the use of bariatric
surgery in the treatment of CP–HyOb. We also compare these results to those reported
for other populations of HyOb, including Prader–Willi Syndrome, Bardet–Biedl syndrome,
and hypothalamic melanocortin signaling defects. While initial reports of bariatric surgery
in CP–HyOb are promising, their limited scope makes it difﬁcult to draw any substantial
conclusions as to the long term safety and efﬁcacy of bariatric surgery in CP–HyOb.There
continues to be a need for more robust, controlled, prospective studies with long term
follow-up in order to better deﬁne the role of bariatric surgery in the treatment of HyOb.
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INTRODUCTION
Craniopharyngiomas (CP) are generally benign, slow-growing
tumors that are thought to arise fromrests of embryonic cells resid-
ing within the remnants of the craniopharyngeal duct or Rathke’s
pouch (Abeloff, 2008). Thus, tumorsmay originate fromanywhere
along the path of the craniopharyngeal duct, from nasopharynx to
tuber cinereum, although most are located in the sellar/parasellar
region (Harwood-Nash, 1994; Karavitaki et al., 2005). Although
histologically benign, these tumors are often locally aggressivewith
invasion of adjacent tissues and structures.While mortality is gen-
erally low, morbidity as a result of tumor mass effect and/or ther-
apy (resection± radiotherapy) is substantial and nearly universal
(Mortini et al., 2011; Winkﬁeld et al., 2011).
Because of the close proximity to the visual nerve tracts,
hypothalamus, pituitary, and ventricular system, CPs predis-
pose patients to a number of adverse endocrine, metabolic,
psychologic, and neurologic sequelae. As a primary result of
the tumor, the majority of patients present with one or more
hypothalamic-pituitary deﬁcits including growth hormone (GH;
∼75%), gonadotropins (∼60%), adrenocorticotropic hormone
(ACTH; ∼30%), thyroid-stimulating hormone (TSH; ∼25%),
and/or antidiuretic hormone (ADH;∼20%;Karavitaki et al., 2006;
Muller, 2008). In addition, approximately one-third can develop
new or additional endocrinopathies following surgical resection.
HYPOTHALAMIC OBESITY
In addition to pituitary hormone deﬁciencies, hypothalamic
involvement has been shown to result in severe metabolic dis-
turbances and weight gain (Muller et al., 2001; Srinivasan et al.,
2004). While a minority (15–20%) of CP patients complain of
weight gain as a presenting symptom,more than 50% develop sig-
niﬁcant obesity following surgical resection (Muller et al., 2004;
Ahmet et al., 2006). This number may be as high as 90% in those
with demonstrable hypothalamic damage, whether from direct
tumor inﬁltration or as a result of surgical and/or radiation ther-
apy (de Vile et al., 1996; Muller et al., 2004). Such pathological
weight gain, termed hypothalamic obesity (HyOb), is often severe,
refractory to therapy, and has a signiﬁcant negative impact on the
quality of life for patients with CP (Muller et al., 2005; Eyal et al.,
2006; Inge et al., 2007).
Over the last 75 years, experiencewith animal and humanmod-
els has shown the basal medial hypothalamus to be a key center of
metabolic regulation by the central nervous system (CNS; Het-
herington and Ranson, 1940; Sorva, 1988). The hypothalamus
receives and integrates a variety of afferent signals communicat-
ing the metabolic state of the organism and adjusts autonomic
outputs with the ideal physiologic outcome of maintaining ade-
quate energy stores. The afferent arm of the homeostatic loop
consists of hormones, such as leptin, insulin, and peptide YY,
www.frontiersin.org February 2012 | Volume 3 | Article 23 | 1
Bingham et al. Bariatric surgery
that target receptor ﬁelds within hypothalamic nuclei to convey
information on meal size, nutrient composition, and adipose tis-
sue stores. In addition, neurons within the hypothalamus directly
sense and respond to nutrients, such as free fatty acids, glucose,
and amino acids.Within the hypothalamus, neuropeptides such as
neuropeptide Y (NPY), agouti-related protein (AgRP), and alpha-
melanocyte stimulating hormone (α-MSH), integrate and convey
this information to other brain centers responsible for controlling
appetite/satiety, thermogenic, andmotor effectors (Schwartz et al.,
2000).
A number of monogenetic obesity syndromes have now been
shown to involve mutations in such regulatory hypothalamic
pathways (Clement et al., 1998; Lubrano-Berthelier et al., 2006;
Savastano et al., 2009;Hochberg andHochberg, 2010). In addition,
several complex genetic syndromes, including Prader–Willi (PWS)
and Bardet–Biedl syndromes (BBS), are associated with obesity,
presumably from hypothalamic dysfunction. PWS results from
the loss of paternally imprinted genes on chromosome 15q11-15
and is characterized by an array of multisystemic defects including
neonatal hypotonia, short stature, hypogonadism, behavioral and
psychiatric phenotypes, aggressive food-seeking behavior, hyper-
phagia, and obesity (Goldstone et al., 2008). PWS patients have
signiﬁcantly elevated levels of the orexigenic hormone ghrelin, a
ﬁnding not observed in other causes of HyOb (Cummings et al.,
2002a; DelParigi et al., 2002). Interestingly, even young, under-
weight patients with PWS exhibit higher BMI-adjusted body fat
and serum leptin levels, suggesting some intrinsic leptin resistance
in PWS (Eiholzer et al., 1999). BBS is a multisystemic disorder
characterized by retinal degeneration, hypogonadism,polydactyly,
renal dysfunction, mental retardation, and obesity resulting from
defects in ciliary function. Hypothalamic dysfunction in these
patients is suggested by the study of mice harboring mutations
in BBS genes. BBS mutants have been shown to be hyperleptine-
mic and have defective hypothalamic leptin signaling (Seo et al.,
2009; Guo and Rahmouni, 2011).
Thus, damage to, or dysfunction of the hypothalamus results
in an inability of the CNS to receive proper feedback. Patients,
thus, inappropriately sense a perpetual state of starvation. To
correct the perceived negative energy balance, efferent outputs
are adjusted to promote caloric intake and decreased caloric
expenditure. Decreased sympathetic activation of β2-,β3-, and α2-
adrenergic receptors reduce skeletal muscle thermogenesis, reduce
adipose tissue lipolysis, and promote pancreatic insulin secre-
tion, respectively. Conversely, increased parasympathetic output
through the vagus nerve slows the heart rate reducing myocar-
dial oxygen consumption, promotes gastrointestinal peristalsis
and substrate absorption, and accentuates post-prandial insulin
secretion (Lustig, 2008). The net result of this reduced sym-
pathetic/parasympathetic ratio is signiﬁcantly decreased energy
expenditure with partitioning of calories away from energy con-
suming tissue such as muscle and toward energy storage depots
such as adipose tissue.
Accumulating evidence supports the hypothesis that CP and
its therapies often result in dysfunction of the normal homeo-
static mechanisms regulating appetite and metabolism. Leptin,
a potent anorexigenic peptide secreted by adipocytes, has been
found to be elevated in CP patients compared to obese controls
suggesting a defect in the normal feedback inhibition of appetite.
In addition, some CP patients have a blunted post-meal increase
in the anorexigenic hormone peptide YY. Hypersecretion of the
orexigenic gastric hormone ghrelin is thought to contribute to
hyperphagia and obesity in PWS, although this does not seem
to be the case in CP where pre-meal ghrelin levels are lower than
weight-matched controls. Recently, however, Roth et al. found that
there may be a reduction in the expected magnitude of post-meal
suppression of ghrelin levels inCP patients (Roth et al., 1998, 2011;
Holmer et al., 2010).
While there are reports of hyperphagia and obsessive food-
seeking behavior after CP (Skorzewska et al., 1989), a number of
studies have now shown that caloric expenditure, and not caloric
intake, may be the largest contributor to post-CP–HyOb (CP–
HyOb). Adults and children with CP–HyOb have been found to
have impaired sympathoadrenal activation in response to hypo-
glycemia, although this defect does not appear to always corre-
late with development of obesity or hypothalamic involvement
(Schoﬂ et al., 2002; Coutant et al., 2003). In a larger study,
CP–HyOb patients were found to have lower levels of urine
catecholamines than BMI-matched controls (Roth et al., 2007),
suggesting decreased sympathetic tone.
As sympathetic tone correlates with spontaneous motor activ-
ity, one might also expect lower levels of physical activity in CP
patients. Indeed, CP patients consistently report reduced physical
activity, even when compared to controls with similar BMI (Roth
et al., 2007). Using accelerometric data, Harz et al. demonstrated
that obese CP patients had decreased spontaneous motor activity
comparedwith age andBMI-matched controls. Using food diaries,
this samegroup showed that caloric intakewas lower inCPpatients
with hypothalamic damage, despite a signiﬁcantly increased BMI
(Harz et al., 2003). These ﬁndings were substantiated by a recent
study by Holmer et al. in 42 adult patients with childhood CP,
where CP patients were found to have a signiﬁcantly reduced basal
metabolic rate when adjusted for body weight, than age and sex
matched controls. Analysis of energy intake showed lower caloric
consumption in CP patients which was attributed to cognitive
restraint in eating (Holmer et al., 2010). Aside from reduced sym-
pathetic drive, the roadblocks to physical activity are substantial
and likely contribute to reduced energy expenditure and risk for
obesity. Neurological and visual deﬁcits may contribute to limited
movement in some CP patients. In addition, there is evidence that
CP patients have disordered sleep patterns secondary to decreased
melatonin and/or secondary narcolepsy causing daytime sleepi-
ness (Muller et al., 2002, 2006). Obstructive sleep apnea (OSA) in
these patients also likely contributes to poor sleep hygiene.
Under- or overtreatment of hormonal deﬁciencies may also
contribute to poor metabolic parameters and weight gain in CP
patients. Glucocorticoid excess is a known cause of signiﬁcant
weight gain, impaired glucose metabolism, sleep disturbance, and
defects in bone metabolism and growth (Debono et al., 2009).
Most signiﬁcantly, excess glucocorticoid dosing has been associ-
ated with increased mortality from cardiovascular disease. In a
large cohort of Scandinavian patients with hypopituitarism, Fil-
ipsson et al. (2006) showed that those receiving higher doses of
glucocorticoid replacement had signiﬁcantly higher waist circum-
ference, total cholesterol, serum triglycerides, and HbA1c. Daily
Frontiers in Endocrinology | Pituitary Endocrinology February 2012 | Volume 3 | Article 23 | 2
Bingham et al. Bariatric surgery
cortisol production rates range from 6 to 8mg/m2/day, much less
than previous estimates (Linder et al., 1990; Esteban et al., 1991;
Kerrigan et al., 1993; Brandon et al., 1999). Thus, the classic adult
dosing of 20mg of hydrocortisone in the A.M. and 10mg in the
P.M., is likely an excessive dose. Unfortunately, no objective test of
adequate glucocorticoid replacement has been shown to be sufﬁ-
ciently consistent to aid in dosing management and patients must
be followed closely for clinical signs of glucocorticoid deﬁciency
or excess.
Hypothyroidism also results in poor metabolic health and is
associated with fatigue, low basal metabolic rate, increased BMI,
and increased cholesterol and triglyceride levels (Kronenberg and
Williams, 2008) and adequate replacement has beneﬁcial effects
on these parameters (Slawik et al., 2007). Management of thyroid
hormone replacement is mademore challenging in CP patients by
the absence of the patient’s own endogenous “thyrostat” as TSH
levels cannot be used to judge adequacy of treatment. The signiﬁ-
cance of this handicap is highlighted in a recent study comparing
free T4 (fT4) levels in TSH deﬁcient patients to those in primary
hypothyroid patients where TSH levels are used to guide therapy.
Nearly 40% of TSH deﬁcient patients were found to have fT4 lev-
els below the 20th centile range compared to 13.4% of primary
hypothyroid patients (Koulouri et al., 2011).
Growth hormone deﬁciency is present in a majority of CP
patients and likely contributes to themetabolic derangements seen
in this patient population. These metabolic effects are particularly
important in adults, where GH replacement results in increased
lean bodymass and decreased body fat (Kronenberg andWilliams,
2008). GH-deﬁciency has been shown to contribute to increased
cardiovascular risk in hypopituitarism (Abs et al., 2006; Verhelst
andAbs,2009). Thedecision to replaceGH inpatientswith aprevi-
ous history of CP remains controversial althoughGH replacement
does not appear to have any adverse effect on reoccurrence rates
of CP in short term follow-up (Muller et al., 2010; Rohrer et al.,
2010).
Hypogonadism and inadequately treated diabetes insipidus
(DI) can also potentiate the effects of hypothalamic damage on
excessive weight gain. Testosterone replacement, in hypogonadal
men has been shown to have beneﬁcial effects on body com-
position, blood pressure, and glucose homeostasis (Katznelson
et al., 1996; Boyanov et al., 2003; Wittert et al., 2003). The effects
of estrogen replacement on weight gain and body composition
are more mixed and unclear, but premenopausal women who
are hypogonadal should be physiologically replaced barring other
contraindications (Norman et al., 2000). Inadequate control of DI
can lead to excessive drinking of calories, poor sleep quality, and
increased appetite (Beccuti and Pannain, 2011).
Altered carbohydrate and insulin dynamics have been shown
to occur with CP and its treatment. While fasting glucose levels
are generally no different from controls, CP patients have an exag-
gerated ﬁrst and second phase insulin response to carbohydrate
challenge (Lustig et al., 1999). Hyperinsulinism in hypothalamic
damage is a result of bothdecreased inhibitory toneby sympathetic
pathways and augmented vagal parasympathetic signaling to the
pancreatic β-cell, and is not primarily a response to insulin resis-
tance. Vagally mediated acetylcholine, acting through M3 mus-
carinic receptors, promotes depolarization of the β-cell through
increased sodium inﬂux, andmobilization of intracellular calcium
stores through activation of the phospholipase C pathway (Miura
et al., 1996). In addition, increased vagal activity stimulates release
of the intestinal peptide glucagon-like peptide-1, itself a potentia-
tor of insulin secretion (Rocca and Brubaker, 1999; Lustig, 2008).
Increased insulin secretion in turn directs calories toward storage
within the adipocyte.
Thus, the disruption of hypothalamic centers that occurs as a
direct result of CP or its treatment creates a situation in which
efferent drives to consume and store energy are disengaged from
afferent signals that would otherwise dampen such drives. The
obesity that results, driven by neural and biochemical stimuli, is
often severe and intractable to therapy.While lifestyle changes such
as caloric restriction and increased exercise should be encouraged,
these interventions alone are often not successful, leaving patients
frustrated with cravings, constant hunger, and lack of progress.
Further, in addition to panhypopituitarism, HyOb patients are
susceptible to the same metabolic derangements seen in other
types of obesity such as diabetes, dyslipidemia, and heart disease
(Srinivasan et al., 2004). For patients already facing signiﬁcant
challenges as a result of their primary disease, the negative impact
of such comorbidities on quality of life adds insult to injury.
Unfortunately, in the last several years pharmacologic agents
available for weight loss treatment have signiﬁcantly declined,
as the most effective agents (i.e., phen–fen, sibutramine) have
been withdrawn from the market for unacceptable side-effect
proﬁles. Small studies in CP of stimulants such as modaﬁnil,
methylphenidate, and dextroamphetamine have been shown to
improve daytime sleepiness, affect, and alertness in HyOb (Mason
et al., 2002; Muller et al., 2006), but none have proven truly effec-
tive at reversing the severe weight gain seen in this condition.
Targeting the hyperinsulinism seen in HyOb, Lustig et al. (2006)
demonstrated that octreotide could induce a modest decrease in
BMI (0.79 kg/m2).A recent preliminary trial of diazoxide andmet-
formin combined therapy demonstrated a slowing of weight gain
with a stabilization of BMI over the 6-months of therapy (Hamil-
ton et al., 2011). Taken as a whole, the efﬁcacy of pharmacotherapy
in treating CP–HyOb is tepid at best. Because CP–HyOb results
from damage to the afferent target centers of the hypothalamus,
agents targeting the efferent pathways to increase metabolic rate
and/or thermogenesismay prove to bemore effective (Bays, 2004).
Newer agents targeting these efferent pathways are desperately
needed.
SURGICAL TREATMENT OF HyOb
Given the limited choices and poor results of pharmacotherapy,
combined with emerging data suggesting that gastrointestinal sur-
gical procedures effectweight loss by altering thebody’sweight reg-
ulatory signaling pathways, several groups have looked to bariatric
surgery as a viable option for producing sustained weight loss
for patients with CP–HyOb. A range of procedures are available
and are generally divided into three categories: restrictive, malab-
sorptive, and hybrid procedures. Restrictive procedures, such as
gastric banding (GB) or vertical banded gastroplasty (VBG), aim
to reduce stomach volume resulting in early satiety and smaller
meal consumption. The natural course that nutrients follow is
not altered, however. Pure malabsorptive procedures including
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jejunoileal and duodenal–jejunal bypass, as well as biliopancreatic
diversion (BPD) involve the diversion of ingested food, bypass-
ing one or more sections of intestine. The former two of these
procedures have largely fallen out of favor secondary to associ-
ated nutritional deﬁcits (Organ et al., 1984). A hybrid procedure,
the Roux-en-Y gastric bypass (RYGB) has become the “gold stan-
dard” and the most commonly performed bariatric surgery for
weight loss. It entails dividing the stomach to create a small gastric
pouchwhich is anastomosed to a roux limbof jejunum.An entero-
enterostomy is then made between the excluded biliopancreatic
limb and the roux alimentary limb (Karra et al., 2010).
Bariatric surgery remains the most effective treatment for
morbid obesity and is indicated for adult patients with a
BMI> 40 kg/m2 or a BMI of >35 kg/m2 and signiﬁcant obesity-
related comorbidities (Pories et al., 1995). More conservative indi-
cations have generally been advocated for weight loss surgery in
adolescent patients (see Discussion and Future Directions). An
extensive body of research has shown that patients often show
measurable improvement in metabolic parameters including glu-
cose homeostasis in the early post-operative period, independent
of weight loss. While the exact mechanisms of this phenomenon
are still unclear, it appears that gastric bypass alters the secretion of
gut hormones that favor improvedmetabolismandmay also coun-
teract certain elements of the orexigenic and energy conserving
hypothalamic response to voluntary weight loss. Indeed, a number
of studies over the last 30 years have shown that GLP-1, an incretin
hormone secreted by enteroendocrine cells of the distal ileum, is
increased following bariatric surgery. The evidence is especially
consistent for bypass procedures, whereas restrictive procedures
have been associated with no change or a decrease in GLP-1 levels
(Sarson et al., 1981; Koopmans et al., 1984; Laferrere et al., 2008).
GLP-1 has been shown to have a number of positive effects
on glucose metabolism including potentiating glucose-dependent
insulin secretion, improving insulin sensitivity, and suppressing
glucagon secretion. In addition, it has been shown to slow gastric
emptying and promote early satiety. GLP-1 exerts these pleiotropic
effect by acting on speciﬁc receptors located on pancreatic β-cells,
peripheral vagal afferent ﬁbers, as well as centrally located neu-
rons (Baggio and Drucker, 2007). In addition, bariatric surgery
has been shown to increase other anorexigenic hormones such
as PYY and decrease orexigenic hormones such as ghrelin (Cum-
mings et al., 2002b; leRoux et al., 2006).Humanand animal studies
appear to indicate that exposure of the distal gut to nutrient-rich,
partially digested food results in increased secretion of hormones
such as GLP-1 and PYY. This altered hormonal milieu accounts
for the greater than 80% remission in diabetes following RYGB,
oftenwithin days toweeks of surgery, and a combination of malab-
sorption, gastric restriction, and hormonal changes that accounts
for the consistent and durable weight loss seen following such
procedures (Buchwald et al., 2004; Karra et al., 2010).
Despite the large body of evidence demonstrating the ben-
eﬁts of bariatric surgery in treating exogenous obesity and its
comorbidities, its role in the treatment of HyOb has yet to be
deﬁned. To date, the existing literature on bariatric surgery in
CP–HyOb is largely limited to case reports and series with short
term follow-up. A PubMed search for “craniopharyngioma” and
“bariatric surgery” results in four citations with a total of eight
patients. Procedures performed include two RYGB, four laparo-
scopic adjustable band (LAGB), one distal gastric bypass, and one
biliopancreatic derivation with duodenal switch.
In the ﬁrst report of RYGB for CP–HyOb, we reported on an
18-year-old male who underwent a successful RYGB with ante-
rior truncal vagotomy (due to the presumed importance of vagal
efferents in CP-related hyperinsulinemia) for massive weight gain
following the resection of a CP 3 years previous. At the time of CP
diagnosis, his BMI was 25 kg/m2. During the 2-years following CP
resection, he developed hyperphagia and signiﬁcant weight gain
(70 kg/year) despite outpatient and inpatient dietary and physi-
cal activity interventions. Signiﬁcant hyperinsulinism was noted
and the patient was started on octreotide therapy with signiﬁ-
cant deceleration in weight gain but no weight loss. At the time
of his bariatric surgery consultation, he had developed severe
OSA, left ventricular hypertrophy, and hypertriglyceridemia. The
post-operative course was signiﬁcant for a 49-kg weight loss
over 2.5 years, although weight appeared to stabilize thereafter
(BMI ∼50 kg/m2). Further, serum triglycerides and left ventric-
ular hypertrophy normalized. Hyperphagia decreased and food
cravings (as measured by a Food Craving Inventory) diminished
for all food types. Ten days following RYGB surgery, there was a
ﬁvefold decrease in fasting insulin, with normalization of fasting
levels by 7months. His post-prandial insulin excursion completely
normalized by 14months.Aswell,measurements of the orexigenic
hormone ghrelin revealed a moderate decrease over the same time
period.
In a different approach,Schultes et al. describe their approach to
bypass surgery in a 29-year-oldmalewith childhoodCP. Following
CP resection 21 years previous, the patient had experienced con-
tinuous weight gain, developed type 2 diabetes, andOSA requiring
continuous positive airway pressure therapy at night.At the timeof
HyOb surgical consultation, this patient was on hormone replace-
ment for panhypopituitarism aswell asmetformin andnateglinide
for diabetes treatment. To promote preoperative weight loss, he
was started on 15mg sibutramine and enrolled in a rigorous super-
vised diet and exercise regimen which resulted in 9 kg weight loss
over 9months. Because bypass-induced hormonal alterationsmay
exert their inﬂuence via hypothalamic mechanisms, it was felt that
this patient,with complete hypothalamic atrophy,may not beneﬁt.
Therefore, a distal gastric bypass, producing a signiﬁcantly shorter
common channel of 80 cm,was performed with the goal of induc-
ing a strong malabsorption component. Following surgery, the
patient experienced a precipitous weight loss, losing over 50 kg
(∼30% of preoperative weight) over 18months. In addition, the
patient exhibited complete resolution of his diabetes and OSA
and distinct reduction feelings of hunger and disinhibition on the
three factor eating questionnaire (Schultes et al., 2009). The post-
operative course was largely uneventful, although the patient did
develop mild nutritional deﬁciencies despite standardized supple-
mentation. These included anemia, deﬁciencies in vitamin D, B12,
and zinc as well as hypoproteinemia.
In a series of four adolescent patients with childhood CP
and obesity, Muller et al. found signiﬁcant weight loss in all
patients after LAGB. Patients participated in the German mul-
ticenter surveillance study on childhood CP termed “HIT-Endo-
Kraniopharyngeom.” The age of the patients ranged from 13 to
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24 years of age and BMI–SDS scores ranged from +7.3 to +13.9.
Following surgery, BMI–SDS scores improved on average by −0.7
per year of follow-up,with follow-up ranging from1.5 to 4.5 years.
Patients also reported signiﬁcant changes in eating behavior, with
reduced food cravings especially for sweets. Quality of life and
functional capacity, measured by a standardized and validated
scale, remained stable following surgery. Of the four patients,
two experienced dislocation of the LAGB resulting in tempo-
rary weight gain and requiring laparoscopic revision. No other
side-effects were reported (Muller et al., 2007).
Rottembourg et al. (2009) reported on two adolescents with
post-CP–HyOb who underwent bariatric surgery as treatment for
morbid obesity associated with signiﬁcant comorbidities. The ﬁrst
was a 12-year-old female diagnosed with CP at age of 6 years. After
gross total resection she developed panhypopituitarism and exhib-
ited a rapidweight gain of 20 kg in the ﬁrst 6months.At the time of
RYGB her BMI was 65 kg/m2 and she had developed dyslipidemia,
hepatosteatosis, frequent respiratory tract infections, and evidence
of hypoventilation. Postoperatively, she demonstrated sustained
weight loss over 4 years (BMI 43 kg/m2 at last follow-up). In
addition, dyslipidemia normalized, sleep patterns improved, and
she had no further respiratory infections. She was subsequently
diagnosed with ﬁbromyalgia and symptomatic hyperuricemia,
which were treated with regular analgesia and allopurinol. She
also required ongoing treatment for depression. In addition, she
developed a dumping-type syndrome (pallor, diaphoresis, and
shakiness following meals) without associated hypoglycemia. The
second patient was a 15-year-old male, diagnosed with CP at age
of 4 years, also with panhypopituitarism and rapid weight gain
following gross total resection. Comorbidities included dyslipi-
demia,hepatosteatosis, andhyperinsulinism.At the age of 14 years,
a trial of octreotide led to no reduction of weight gain. At the
time of bariatric surgery, his BMI was 42 kg/m2. Given that the
underlying cause of obesity was biological and would be present
life-long, the surgeons involved felt that a diversionary surgical
procedure would be a better option than LAGB. Following a BPD
with duodenal switch, his BMI decreased to 32 kg/m2 over the
2-year follow-up. The post-operative course was complicated by
bradycardia requiring pacemaker placement, and stenosis of the
distal surgical anastomosis requiring several laparoscopic repairs.
Overall, both patients exhibited robust, sustained weight loss with
resolution of metabolic comorbidities.
The efﬁcacy of bariatric surgery for weight loss has also been
examined in other HyOb patient populations. Scheimann et al.
recently reported a retrospective critical analysis of bariatric pro-
cedures in PWS. PWS is a complex genetic disorder that results
in marked hyperphagia and obesity felt to be secondary to hypo-
thalamic dysfunction. The critical analysis revealed that a number
of procedures, including BPD, RYGB,VBG, and endoscopic intra-
gastric balloon placement have been used in this population. A
review of 60 PWS patients highlighted the limited effectiveness
and concerning safety proﬁle of operations for weight loss in
this unique population (Scheimann et al., 2008). In the short
term, there appears to be some limited weight loss that is vari-
able across different procedures. For RYGB, average weight loss
was 4.2% for PWS patients after 6months. Twelve month and
24month follow-up revealed 6.5 and 2% weight loss, respectively.
This weight loss is far less than the 35% reduction in BMI we see
1 year after RYGB for adolescents who do not have PWS. Five year
follow-up, while limited, showed only a 2.4% weight loss in PWS
patients after RYGB (n = 9). Long term weight loss was worse
with VBG, with PWS patients experiencing a 3.5% weight gain
after 5 years (n = 2). Patients undergoing BPD had higher weight
loss of 27.6% at 12-months, but nearly half regained weight within
2–5 years. In addition, the report highlights what appears to be a
highpost-operative complication rate,with 47%requiring surgical
revision after RYGB and 27% experiencing acute gastric dilation
(Scheimann et al., 2008).
Bariatric surgery has also been reported in an adolescent patient
with BBS. Patients with BBS demonstrate hyperphagia and obe-
sity which have been linked to disruption of primary cilia in
POMC neurons in the hypothalamus and possibly to altered
leptin receptor functioning. In this 16-year-old with a BMI of
53 kg/m2,RYGB resulted in a 33%reduction inBMI 3 years follow-
ing surgery (Daskalakis et al., 2010). Improvement in hypertension
and hyperuricemia was also observed.
Finally, as melanocortin 4 receptor (MC4R) variants represent
themost commonmonogenetic formof HyOb in humans, it is rel-
evant to assess the outcome of bariatric surgery in individuals with
documented MC4R mutations. Surgical experience in this special
group of HyOb patients is very limited. A group of investigators
at the University of California San Francisco (UCSF) described
surgical outcomes in an adolescent patient with a complete loss of
functionmutation atMC4R. This 18-year-oldmale presentedwith
a preoperative weight of 166 kg and BMI of 54 kg/m2 and under-
went bilateral truncal vagotomy and laparoscopic adjustable GB.
In this patient, the surgical intervention did not result in success-
ful weight loss. Indeed, after an initial modest weight reduction
of 12 kg over the ﬁrst 4months, the patient regained weight and
by 1 year was 6.5 kg over his preoperative weight. Several features
of the case however are relevant to interpretation of the outcome.
First, the patient had moved away to college 4months prior to
the operation, and had in that time experienced a 66-kg weight
gain. Also, the patient returned for only two band adjustments in
the 1-year period of time, which is markedly less than the typi-
cally recommended post-operative adjustment schedule. Finally,
the authors described an insatiable hunger 1 year after the oper-
ation, which was almost certainly a factor contributing to weight
gain (Aslan et al., 2011b).
In a more recent publication from the same group at UCSF, the
ﬁrst report of an experience with gastric bypass in the setting of
mutant MC4R contrasts with the results obtained after GB. Aslan
et al. analyzed 1 year outcomes of four adults with heterozygous
MC4R mutations in comparison to matched controls with nor-
malMC4R gene sequences. Excess weight loss (EWL) in these four
subjects was identical to the 60–70% EWL seen in matched con-
trols. There was no mention of changes in post-operative appetite
in these patients, nor any changes in metabolic features in this
cohort (Aslan et al., 2011a).
DISCUSSION AND FUTURE DIRECTIONS
Hypothalamic obesity is observed in a high percentage of patients
with CP, resulting in signiﬁcant comorbidities and negatively
impacting quality of life. Unfortunately, few treatments have
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proven effective in this patient population. First line therapy for
HyOb should include aggressive lifestyle modiﬁcation including
appropriate caloric intake and activity. Pituitary hormone deﬁ-
ciencies, if any, should be replaced and doses optimized. As men-
tioned previously, glucocorticoid replacement should be targeted
at replacement doses (8–10mg/m2/day hydrocortisone equiva-
lent) and patients should be given the lowest dose possible that
is adequate to avoid symptoms of adrenal insufﬁciency. Thyroid
replacement should generally target the fT4 at the upper third
of the normal range and patients should be clinically and bio-
chemicallymonitored for signs/symptoms of hyper- and hypothy-
roidism (Rose, 2010). The decision to replace GH should be made
in consultation with the patient, family, and other team mem-
bers such as their oncologist and neurosurgeon. If done, GH doses
should be titrated to keep IGF-1 levels within the median range.
Ideally,othermedical treatments aimed speciﬁcally at ameliorating
weight should be pursued through approved protocols at centers
capable of collecting outcomes data on a sufﬁciently large number
of patients so that risks and beneﬁts of treatment can bemore pre-
cisely deﬁned. This is especially important with respect to bariatric
surgery in this population.
Here, we have reviewed the current body of published research
on bariatric surgery in CP–HyOb. We have also included sev-
eral published reports of bariatric surgery in other populations of
HyOb, including PWS, BBS, and patients with MC4R mutations.
While the limited scope of these reports makes comparison dif-
ﬁcult, the experience in PWS patients demonstrates that all cases
of HyOb should not be treated equally. Likely as a result of the
multisystemic nature of their disorder, PWS patients have a sig-
niﬁcantly increased incidence of complications following bariatric
surgery without the beneﬁts of sustained weight loss. In addition,
it appears that early dietary interventions are able to partially abro-
gate weight gain this population (Schmidt et al., 2008). Thus, the
risk–beneﬁt ratio of bariatric surgery in PWS does not appear to
be favorable.
The initial reports of bariatric surgery in CP–HyOb and
patients with MC4Rappear more promising, but again, their lim-
ited scope makes it difﬁcult to draw any substantial conclusions as
to the long term safety and efﬁcacy of these procedures in this
population. The limited number of cases inhibits comparison
among various procedures. For instance, how does RYGB com-
pare to LAGB with regard to long term, sustained weight loss, or
with regard to safety and side-effects? In addition, more work is
needed to understand the hormonal alterations that occur in CP–
HyOb following bariatric surgery. Are such alterations similar to
those seen in diet-induced obesity? If not,why? If so, do CP–HyOb
patients derive the same beneﬁts given their underlying hypothal-
amic damage? If hyperinsulinism is an underlying factor in the
development of HyOb, will patients beneﬁt or be harmed from
increased levels of the insulin secretagogues such as GLP-1. Will
potentiating insulin secretion place these patients at higher risk
of hypoglycemia secondary to the mismatch of insulin secretion
and carbohydrate absorption? These and other questions remain
unanswered by the current body of research in this population and
should be the subject of future work.
In addition, as 50% of patients diagnosed with CP are chil-
dren, there are seriousmedical, psychological, and ethical concerns
regarding bariatric surgery that must be considered in this pop-
ulation (Inge et al., 2004). Generally, adolescent candidates for
bariatric surgery must meet more conservative patient selection
criteria than are acceptable in adults. However, exact criteria are
still of some debate. In 2008, the Endocrine Society, in conjunction
with the Pediatric Endocrine Society, published a Clinical Practice
Guideline on the Prevention and Treatment of Pediatric Obesity,
wherein the task force recommended limiting bariatric surgery
to adolescents with a BMI≥ 50 kg/m2 or a BMI≥ 40 kg/m2 with
signiﬁcant, severe comorbidities. In addition, the task force rec-
ommended that candidates have attained Tanner 4 or 5 pubertal
development and near-ﬁnal adult height, experienced continued
weight gain despite following a formal program of lifestyle modi-
ﬁcation, and belong to a stable, medically competent family unit.
The patient and family should understand that bariatric surgery
is not a cure for obesity, but rather an adjunct to a continued
commitment to lifestyle modiﬁcations in diet and activity. The
surgery should be performed by an experienced surgeon in a
medical center employing a team capable of long term follow-
up and participating in a study of bariatric surgery outcomes.
These recommendations largely agree with guidelines previously
published and advocate the priority of avoiding unforeseen com-
plications associated with life-long exposure to anatomical and
functional alterations above the value of weight loss and ame-
lioration of obesity-related complications provided by bariatric
surgery (August et al., 2008).
More recently, Pratt et al. (2009) suggest that adolescents with
a BMI≥ 35 kg/m2 and serious comorbidities including Type 2
diabetes, moderate to severe OSA, and/or pseudotumor cerebri
or those with BMI≥ 40 kg/m2 with less serious comorbid condi-
tions such as hypertension, dyslipidemia, gastroesophageal reﬂux
disease, and/or psychosocial stress should be considered as can-
didates for bariatric surgery. While concurring with the other
physical, lifestyle, and psychosocial criteria previously published,
they use several lines of evidence to defend the lower BMI criteria.
First, they cite data to indicate that patient safety and weight loss
outcomes for extremely obese adolescents who undergo bariatric
surgery are comparable to, or better than, those seen in adults.
Second, even with the lower BMI criteria of 35 kg/m2, candidates
under the age of 18 would still be above the 99th BMI percentile
and be at substantially increased risk for short and long termmed-
ical comorbidities. Third, they stress that selection for bariatric
surgery during adolescence should be closely linked to obesity-
related comorbidities. The less severe comorbidities and/or fewer
risk factors for long term disease, the higher the BMI cut point
should be before considering bariatric surgery. Finally, some have
suggested that because younger patients will generally have fewer
advanced comorbidities, early bariatric surgery may decrease the
risk of future perioperativemortality, assuming the needed surgery
is delayed until adulthood (Garcia and DeMaria, 2006).
Importantly, none of the guidelines for bariatric surgery
directly addresses the use of bariatric surgery in HyOb generally
or CP–HyOb in particular. In general, we believe that most cri-
teria from the published guidelines can be applied to the HyOb
patients, especially in adults. Whether one or more of the pub-
lished criteria should be modiﬁed in the context of children and
adolescents is subject to ongoing debate. Given what is known
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about the natural history of HyOb, its resistance to diet and
lifestyle modiﬁcation, and the extreme and progressive weight
gain involved, some may consider bariatric surgery appropriate
at ages currently considered too young in patients with exogenous
obesity. However, in general, the younger the patient the more
compelling and serious the comorbidities must be to justify surgi-
cal intervention. Because of the need for life-longmedical support,
optimal care of HyOb patients will be best met in the setting of
tertiary care centers where they can receive treatment in a coor-
dinated,multidisciplinary fashion. Teammembers should include
the primary care physician and as needed subspecialists in neu-
rosurgery, neurology, oncology, endocrinology, bariatric surgery,
and mental health. Ideally, ancillary support by nutrition, phys-
ical therapy, nursing, and social work should also be available.
Patients and families choosing to undergo bariatric surgery should
be properly informed regarding speciﬁc risks and beneﬁts asso-
ciated with surgical weight loss and age appropriate consent or
assent obtained. To facilitate needed research in this area, patients
should be encouraged to enroll in available databases and research
protocols.
These early reports of outcomeof surgicalweight loss treatment
of HyOb are limited in scope and number, but give us a glimpse
of the possible role of surgery in treatment of these conditions.
They also make evident the need for more robust, controlled,
prospective studies with long term follow-up in order to better
deﬁne the role of medical as well as surgical therapies in the treat-
ment of HyOb. In order to ultimately understand the outcome
of surgical therapy for HyOb, sufﬁciently long follow-up of sufﬁ-
cient numbers of similar patients who undergo surgery as well as
non-surgical controls will be required. Non-human surgical mod-
els might also in the future permit a better understanding of the
mechanisms of obesity, and the importance of tailoring speciﬁc
operative elements to each unique population.
Research in this important area is hampered by the difﬁculty of
assembling a sufﬁciently large cohort of CP–HyOb patients. Given
the relative rarity of the condition, it would take a single insti-
tution many years to put together a study large enough to reach
valid, persuasive conclusions regarding the treatment of HyOb –
surgical or otherwise. In order to increase public awareness of
HyOb, facilitate future research and ultimately improve the man-
agement of HyOb, the International Registry for HyOb Disorders
(www.IRHOD.org) has been established. The web-based interface
will permit both healthcare providers and patient/families to easily
enter basic information regarding their HyOb case. The systematic
accumulation of a large world-wide cohort of patients with HyOb
will facilitate recognition of individuals eligible for participation
in studies of HyOb and its treatment. This registry, therefore, has
potential to ﬁll many of the numerous knowledge gaps around
pathogenesis, coexisting disease, and treatment outcomes for this
debilitating form of obesity.
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